Where do you lose weight first on tirzepatide or semaglutide?
We found no study showing where weight goes first on tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy), and the US Zepbound and Wegovy labels name no body area. In a SURMOUNT-1 scan substudy, tirzepatide cut estimated deep belly (visceral) fat by 40%, against 7% on placebo, but about a quarter of the weight lost was lean mass.
Is there a set order for where weight comes off?
We found no study tracking the order of fat loss by body area, and the US Zepbound and Wegovy labels name none.12
The SURMOUNT-1 tirzepatide substudy scanned people before treatment and at week 72, so it cannot show which area changed first.3 A 47-person semaglutide study scanned people before treatment and at week 12, with no comparison group.4 Fat fell in the belly, hips, arms and legs, and abdominal fat fell most in percentage terms.4
A 22-week diet and exercise study of 180 adults, without these medicines, found the trunk lost the largest share of fat, then the legs, then the arms.5 It did not measure which area went first.5
A 2026 review of 44 papers linked the “Ozempic face” look mainly to the speed and amount of weight loss.6 It said the evidence is mostly low-level.6
Do tirzepatide and semaglutide reduce belly fat?
In SURMOUNT-1's scan substudy, estimated deep belly (visceral) fat fell 40% on tirzepatide and 7% on placebo at week 72.3
In STEP 6, a trial in East Asian adults, CT scans in a subset showed visceral fat area fell 40.0% on semaglutide 2.4 mg and 6.9% on placebo at week 68.17
Each maker funded its study: Eli Lilly for the 160-person SURMOUNT-1 analysis, Novo Nordisk for STEP 6.317 The SURMOUNT-1 visceral fat result was worked out after the trial.3
In the US Zepbound label, waists shrank 18.5 cm on 15 mg and 4.0 cm on placebo at week 72.1 The UK Wegovy SmPC (product information) reports 13.5 cm on 2.4 mg and 4.1 cm on placebo at week 68.7 These are averages from separate trials, so they do not compare the two medicines.17
A review covered 89 studies of diet, exercise, drugs and surgery. Visceral fat fell more in percentage terms than fat under the skin, but less in absolute amount.8 Its authors concluded that no treatment preferentially targets visceral fat.8
These figures come with risks, including the lean mass and gallstone results below and the warning signs in the red box.
What else is lost along with fat?
Lean mass, meaning body tissue other than fat and bone, fell too in SURMOUNT-1's scan substudy.3
Fat mass fell 34% on tirzepatide against 8% on placebo, and lean mass fell 11% against 3%.3 Lean mass made up about a quarter of the weight lost in both groups.3 The study did not measure muscle separately.3
The US Zepbound and Wegovy labels both say fat mass falls more than lean mass.12 The UK Mounjaro SmPC says the weight reduction is mostly due to reduced fat mass.16
Weight loss brings other risks. The US Wegovy label warns that substantial or rapid weight loss can raise the risk of gallbladder disease.2 Gallstones affected 1.6% on Wegovy injection against 0.7% on placebo, and 1.1% on Zepbound against 1% on placebo.12 Each entry under In your country links to a guide on side effects.
Can exercise or the injection site decide where fat goes?
A 2022 review of 13 exercise studies found that training one body area did not reduce fat in that area.9
One small 2023 trial disagreed.10 In 16 overweight men, trunk fat fell 697 g more with treadmill running plus abdominal exercise than with treadmill running alone.10 Total fat fell similarly in both groups.10 Diet was not controlled, and only men took part.10
The US Zepbound and Wegovy labels list three injection areas and say to rotate sites with each dose.12 Neither label says the site changes where fat is lost.12
What do people on GLP-1 medicines report about where weight goes first?
From public patient forums: 342 Reddit threads in r/Zepbound, r/Mounjaro, r/mounjarouk, r/Semaglutide, r/WegovyWeightLoss and r/Ozempic, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Not studied Many say the belly, waist or love handles lag or go last. Several say the belly went first, so reports disagree. We found no study of the order.
- Not studied Several notice the face, chin or neck changing early, and several notice fingers, wrists or feet. We found no study of how early these areas change.
- Not studied Several say their breasts got smaller or softer, while several others saw little change. We found no study measuring breast size on these medicines.
- Partly matches one study Several say the bottom or hips flattened, and several say hard seats became uncomfortable. One 47-person semaglutide scan study found fat fell around the hips and upper thighs, but we found no study of body shape or seat comfort.4
Advice people share
- Matches the review Several say you cannot choose where fat goes. A 13-study review agrees, though one small trial found otherwise.910
- Matches the advisory Many advise strength training to keep muscle. A joint advisory from four US medical and nutrition societies recommends resistance training to preserve muscle and bone during GLP-1 treatment.13
- Matches the NHS Several suggest asking about lipoedema if the legs stay out of proportion, though commenters are often guessing. The NHS lists limbs out of proportion as a symptom and advises seeing a GP.11
- FDA and label say otherwise Several posts promote unapproved peptides for belly fat. The FDA says unapproved versions of GLP-1 medicines do not get its review for safety, effectiveness and quality. That FDA page does not cover other peptides.12 A few suggest doses outside the label. The US Zepbound label sets fixed dose steps, with none aimed at one body area.1
In your country
The figures above come from US labels, UK SmPCs and published studies, while the brands sold and the labels we opened differ by country.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: We did not open Australia's Product Information for this page, so it relies on the US labels and UK SmPCs.
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: We did not open Canada's Product Monographs for this page, so it relies on the US labels and UK SmPCs.
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: We could not read the EU product information used in France, so this page relies on the US labels and UK SmPCs.
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not read the EU product information used in Germany, so this page relies on the US labels and UK SmPCs.
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We did not open an Indian label for this page, so it relies on the US labels and UK SmPCs.
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We did not open a Saudi label for this page, so it relies on the US labels and UK SmPCs.
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We did not open a UAE label for this page, so it relies on the US labels and UK SmPCs.
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: We read the UK Wegovy SmPC in full and part of the UK Mounjaro SmPC, so this page also relies on the US labels.
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor right away if you have upper stomach pain, fever, yellowing of the skin or eyes, or clay-coloured stools, which can be gallbladder symptoms.1 If severe stomach pain will not go away and you are not already getting emergency care, the US Zepbound Medication Guide says to stop the medicine and call your provider right away.1 See a doctor about a lump or swelling in your breast, chest or armpit, or a breast or nipple change that is unusual for you.15
Read the full picture
Related questions
Sources
- US Zepbound (tirzepatide) prescribing information and Medication Guide. Eli Lilly
- US Wegovy (semaglutide) prescribing information, revised June 2026. DailyMed
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. Funded by Eli Lilly. PMC11965027
- Effects of once-weekly semaglutide on regional body composition in overweight or obese adults. Metabolism and Target Organ Damage. 2026;6:15. oaepublish.com
- Benito PJ, et al. Influence of previous body mass index and sex on regional fat changes in a weight loss intervention. Phys Sportsmed. 2017;45(4):450-457. Abstract record, BISp-Surf
- Lee KWA, et al. Ozempic Face: An Update and Critical Review. Journal of Cosmetic and Regenerative Medicine. 2026;1(1):19. jcrm.jams.pub
- UK Wegovy 2.4 mg FlexTouch (semaglutide) SmPC. emc
- Merlotti C, et al. Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis. Int J Obes. 2017;41(5):672-682. doi.org/10.1038/ijo.2017.31
- Ramirez-Campillo R, et al. A proposed model to test the hypothesis of exercise-induced localized fat reduction (spot reduction), including a systematic review with meta-analysis. Human Movement. 2022;23(3):1-14. Human Movement
- Abdominal aerobic endurance exercise reveals spot reduction exists: a randomized controlled trial. Physiological Reports. 2023;11(22):e15853. PMC10680576
- NHS. Lipoedema. nhs.uk
- US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. fda.gov
- Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Obesity Pillars. 2025. doi.org/10.1016/j.obpill.2025.100181
- MedlinePlus, US National Library of Medicine. Recognizing medical emergencies, giving the American College of Emergency Physicians' warning signs. medlineplus.gov
- NHS. Symptoms of breast cancer in women. nhs.uk
- UK Mounjaro KwikPen (tirzepatide) SmPC. emc
- Kadowaki T, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193-206. Funded by Novo Nordisk. PubMed 35131037
Last checked Nov 9, 2026 · Next review due Nov 9, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 9, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write